METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for pancreatic cancer: trial tests drug to boost chemo and prevent blood clots
Disease control Recruiting nowThis study is testing a new drug, pegcetacoplan, added to a standard chemotherapy regimen for people with advanced pancreatic cancer that has spread. The main goals are to see if the combination is safe and if it can help control the cancer. Researchers also want to see if the ne…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Breakthrough trial targets 'Undruggable' cancer mutations in pancreatic and colon tumors
Disease control Recruiting nowThis study is testing new targeted drugs called RAS inhibitors in combination with standard cancer treatments for people with advanced colorectal or pancreatic cancer. The goal is to find safe and effective doses while seeing if these new drug combinations can help control cancer…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Breakthrough trial aims to extend lives in deadly pancreatic cancer
Disease control Recruiting nowThis study is testing whether adding two new drugs (TQB2868 and anlotinib) to standard chemotherapy helps people with advanced pancreatic cancer live longer. About 566 participants with newly diagnosed metastatic pancreatic cancer will receive either the new drug combination or s…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Radical stem cell combo aims to outsmart tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer. The goal is to see if a combination of high-dose chemotherapy drugs, vitamins, and the patient's own stem cells is safe and can overcome the cancer's resistance to treatment.…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for tough pancreatic cancer? early trial tests drug combo
Disease control Recruiting nowThis early-stage trial is testing whether adding a new experimental drug called zunsemetinib to a standard chemotherapy regimen (mFOLFIRINOX) is safe and tolerable for people with newly diagnosed metastatic pancreatic cancer. The main goal is to find the right dose of the new dru…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough pancreatic cancers: experimental drug combo enters human testing
Disease control Recruiting nowThis early-stage trial is testing whether adding a new oral drug called CA-4948 to standard chemotherapy is safe and tolerable for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The main goal is to find the highest dose that patients can h…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New scan could reveal if pancreatic cancer treatment is working sooner
Diagnosis Recruiting nowThis study is testing a new, experimental type of MRI scan that looks at how a pancreatic tumor uses energy. The goal is to see if this scan can tell doctors earlier than current scans whether a patient's standard cancer treatment is working. About 70 adults with advanced pancrea…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Mar 06, 2026 15:37 UTC
-
New hope to fight devastating weight loss in pancreatic cancer
Symptom relief Recruiting nowThis study is testing whether a new drug called ponsegromab can help people with advanced pancreatic cancer who are experiencing severe weight loss (cachexia). Participants will receive either ponsegromab or a placebo as an injection every four weeks, in addition to their standar…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Mar 17, 2026 12:55 UTC
-
Blood test could speed up cancer treatment decisions, study hopes
Knowledge-focused Recruiting nowThis study is testing whether a simple blood test can tell doctors if chemotherapy is working for metastatic pancreatic cancer faster than the current standard of waiting 8 weeks for scans. Researchers will measure tumor DNA in the blood of 50 participants at different time point…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists probe six drugs in race to outsmart pancreatic cancer
Knowledge-focused Recruiting nowThis early study aims to understand how six different investigational drugs affect the biology of pancreatic cancer tumors. It will enroll about 90 adults with various stages of pancreatic cancer. Participants take one of the drugs for about 10 days before a scheduled biopsy or s…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Scientists probe new Drug's effect on deadly pancreatic tumors
Knowledge-focused Recruiting nowThis early research study aims to understand how an experimental drug called OMO-103 affects pancreatic cancer cells in patients. Twelve adults with advanced pancreatic cancer will receive two infusions of the drug and undergo tumor biopsies to see if it changes the tumor's biolo…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC